{"filings":[{"id":1249518,"accession_number":"0001493152-26-029924","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2026-06-24T20:10:04+00:00","items":["5.07"],"status":"ready","headline":"Daxor shareholders elect all six director nominees and ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All six director nominees elected for terms expiring in 2027.","Henry D. Cremisi, MD, Edward Feuer, Joy Goudie, Esq., and Caleb DesRosiers, Esq. each received ~4,436,972 votes for.","Michael Feldschuh and Jonathan Feldschuh elected with 4,116,310 and 4,111,640 votes for, respectively.","Bush & Associates, CPA ratified as independent registered public accounting firm with 4,423,295 votes for, 19,839 against, 401 abstain.","Annual meeting held June 23, 2026; no other matters submitted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112992,"accession_number":"0001493152-26-003615","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2026-01-26T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Daxor raises ~$8.1M in registered direct offering of 765,958 shares at $11.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 765,958 shares at $11.75 per share for net proceeds of approx. $8,142,006 after fees.","Offering closed January 26, 2026; Lake Street Capital Markets acted as placement agent.","Shares registered under shelf registration statement on Form N-2 (File No. 333-281622) effective Jan 20, 2026.","Company did not specify use of proceeds; typical for working capital and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":112991,"accession_number":"0001493152-26-003302","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2026-01-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor files 8-K with investor presentation; no details available from provided text","summary_kind":"llm","event_type":"other","confidence":"low","bullets":["Daxor Corporation issued a regulatory filing attaching an investor presentation on January 23, 2026.","Exhibit 99.1 is the investor presentation, but its content was not included in the text provided for analysis.","No financial results, guidance, or material developments are available from this filing.","Confidence is low due to absence of exhibit content."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145960,"accession_number":"0001641172-25-022513","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor receives FDA 510(k) clearance for next-gen blood volume analyzer","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA 510(k) clearance (K251087) for patent-pending rapid, hand-held BVA device.","Device provides results 3x faster, weighs 7 lbs, delivers lab-grade precision.","Clinical data: BVA-guided care reduced heart failure mortality by 86% (p<0.001), ICU mortality by 66%.","Over 75,000 tests shipped; developed under U.S. Army/DHA contract.","Management expects high demand driven by speed, simplicity, precision."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":145959,"accession_number":"0001641172-25-017303","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Daxor reports annual meeting voting results; all director nominees elected, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; votes for ranged from 3,473,576 to 3,493,651.","Ratification of Bush & Associates as independent auditor approved with 3,494,574 for, 100 against, 876 abstain.","Annual meeting held June 24, 2025; no other material matters voted upon."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214713,"accession_number":"0001493152-24-028308","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Daxor holds annual meeting; re-elects six directors, ratifies auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected with over 3.5M votes for each; no new directors.","Citrin Cooperman LLP ratified as independent auditor with 4.76M votes for, 28.4K against.","Broker non-votes of 1.23M shares on director elections due to non-discretionary items."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233853,"accession_number":"0001493152-24-022735","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Daxor resolves Nasdaq audit committee deficiency with appointment of Caleb DesRosiers","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Daxor on May 30, 2024 of non-compliance with audit committee rule due to death of James A. Lombard.","Company appointed Caleb DesRosiers to audit committee; Nasdaq staff determined compliance and closed the matter.","No further action required; listing continues on Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251830,"accession_number":"0001493152-24-011110","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2024-03-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor acquires worldwide rights to Volumex, Megatope, and Glofil from Iso-Tex Diagnostics","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["No upfront payment; seller-financed with monthly installments starting after manufacturing transition in 6–9 months.","Deal expected to be immediately accretive and cash flow positive due to higher margins from in-house production.","Glofil (GFR diagnostic) adds recurring revenue stream and cross-selling opportunity to existing hospital customers.","Volumex and Megatope radiopharmaceuticals for blood volume analysis will be produced at Daxor's Oak Ridge facility.","Transaction subject to customary closing conditions including applicable regulatory approvals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251829,"accession_number":"0001493152-24-000035","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2024-01-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor submits next-gen BVA to FDA for 510(k)/CLIA-waiver; clearance expected H1 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Submission via dual 510(k)/CLIA-waiver pathway to FDA for next-generation blood volume analyzer.","New device designed to be three times faster, simpler, portable, and capable of bedside analysis.","Development funded under contract by U.S. Department of Defense.","Potential FDA clearance is expected during the first half of 2024.","Current BVA-100 is only FDA-cleared diagnostic for direct blood volume measurement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269362,"accession_number":"0001493152-23-042822","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2023-11-28T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Daxor allocates $550K of May 2023 offering proceeds to hematocrit capability development","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["Net proceeds of $3.56M from May 22, 2023 public offering of 410,260 shares at $9.75/share.","$550,000 reserved for proprietary hematocrit capability for next-generation technologies.","Development expected over 12 months, supported by Department of Defense efforts.","Funds are part of the previously stated use of proceeds for next-gen technology development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":269361,"accession_number":"0001493152-23-038564","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2023-10-27T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Daxor allocates $1.9M of May 2023 offering proceeds to optical blood volume analyzer development","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net proceeds of $3,555,532 from 410,260 shares at $9.75/share in May 2023 public offering.","$1,900,000 reserved for next-generation optical blood volume analyzer systems development.","Development expected over 24 months in conjunction with Department of Defense technology efforts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286340,"accession_number":"0001493152-23-024471","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2023-07-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Daxor shareholders elect seven directors, ratify auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected James Lombard, Henry Cremisi, Edward Feuer, Joy Goudie, Michael Feldschuh, Jonathan Feldschuh, Caleb DesRosiers as directors.","All director nominees received 3.485M to 3.508M votes for; broker non-votes were zero.","Ratified Steven Zelin & Associates as independent auditor with 3.569M for, 16.7k against.","Annual meeting held July 11, 2023; results reported July 13, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":306188,"accession_number":"0001493152-23-019148","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2023-05-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor closes $4.0M public offering of 410,260 shares at $9.75/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed underwritten public offering of 410,260 shares at $9.75 per share, raising $4.0M gross.","Underwriters granted 45-day option to purchase up to an additional 61,539 shares.","Proceeds to be used for working capital, product development, capital expenditures, acquisitions, or debt repayment.","Maxim Group LLC acted as sole book-running manager; Joseph Gunnar & Co. as co-manager.","Shelf registration statement on Form N-2 effective July 16, 2021; final prospectus filed with SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":343134,"accession_number":"0001493152-22-033010","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2022-11-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor closes $2.1M underwritten public offering of 221,050 shares at $9.50/sh","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed offering of 210,527 shares plus partial overallotment of 10,523 shares, total 221,050 shares.","Gross proceeds ~$2.1M; net proceeds for working capital, product development, and potential acquisitions.","Joseph Gunnar & Co. acted as sole book-running manager; Maxim Group as advisor.","Shares sold at $9.50 each; offering made via shelf registration effective July 2021."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378503,"accession_number":"0001493152-22-018103","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Daxor annual meeting elects directors, approves compensation plan and written consent amendments","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected with majority votes; broker non-votes ranged from 504,940 to 540,940.","Ratification of Baker Tilly as independent auditor approved: 4,059,926 for, 15 against.","Amendment to 2020 Incentive Compensation Plan (increase authorized shares) approved: 3,543,158 for, 12,859 against.","Amendment to Certificate of Incorporation to allow stockholder action by less than unanimous written consent approved: 3,466,809 for, 89,134 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396763,"accession_number":"0001493152-22-002990","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2022-02-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Daxor begins trading on Nasdaq Capital Markets, will ring Opening Bell on Feb 4, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Daxor commenced trading on Nasdaq Capital Markets effective Feb 2, 2022, moving from NYSE American (ticker DXR).","CEO Michael Feldschuh to ring Nasdaq Opening Bell on Feb 4, 2022 at MarketSite in Times Square.","Management expects improved stock visibility, trading liquidity, and institutional investor exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396762,"accession_number":"0001493152-22-002107","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2022-01-24T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Daxor appoints Caleb DesRosiers to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Caleb DesRosiers, JD, MPA, appointed to Board effective January 18, 2022, until next annual meeting.","Currently senior principal at Valuate Healthcare (part of Omnicom); previously Chief Strategy Officer at PrescribeWellness.","Board determined Mr. DesRosiers meets NYSE independence standards and qualifies under Regulation S-K Item 407(a).","He has no beneficial ownership of Daxor stock or rights to acquire stock as of appointment date.","Will receive standard non-employee director compensation as described in the company's proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396761,"accession_number":"0001493152-22-001729","cik":27367,"company_name":"DAXOR CORP","ticker":"DXR","form_type":"8-K","filed_at":"2022-01-20T23:59:59+00:00","items":["3.01","9.01"],"status":"ready","headline":"Daxor to transfer stock listing to Nasdaq Capital Market on Feb 2, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective Feb 2, 2022, Daxor's common stock will trade on Nasdaq Capital Market under ticker DXR.","Trading on NYSE American will cease at market close on Feb 1, 2022; no change to ticker symbol.","CEO Michael Feldschuh expects the move to improve stock visibility, trading liquidity, and institutional exposure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":66200000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}